List of Excipients in Branded Drug DOTTI

Generic Drugs Containing DOTTI

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals LLC	estradiol	65162-989	DIMETHICONOL/TRIMETHYLSILOXYSILICATE CROSSPOLYMER
Amneal Pharmaceuticals LLC	estradiol	65162-989	DIPROPYLENE GLYCOL
Amneal Pharmaceuticals LLC	estradiol	65162-989	OLEYL ALCOHOL
Amneal Pharmaceuticals LLC	estradiol	65162-989	POVIDONE
Bryant Ranch Prepack	estradiol	72162-2032	DIMETHICONOL/TRIMETHYLSILOXYSILICATE CROSSPOLYMER
Bryant Ranch Prepack	estradiol	72162-2032	DIPROPYLENE GLYCOL
Bryant Ranch Prepack	estradiol	72162-2032	OLEYL ALCOHOL

What are the Most Frequently-Used Excipients in DOTTI?

# Of NDCs	Excipient
6	DIMETHICONOL/TRIMETHYLSILOXYSILICATE CROSSPOLYMER
6	DIPROPYLENE GLYCOL
6	OLEYL ALCOHOL
6	POVIDONE

Last updated: August 2, 2026

ecutive summary: DOTTI is a twice-weekly estradiol transdermal system whose commercial value depends on reliable skin adhesion, controlled estradiol delivery, low irritation, and manufacturing consistency. Its excipient platform is a drug-in-adhesive matrix using acrylic and silicone adhesive components with polymeric backing and release layers. The strongest commercial opportunities are differentiated adhesive systems, smaller or more skin-tolerant patches, manufacturing improvements, and combination hormone-replacement products. New entrants face limited active-ingredient protection, but formulation, process, regulatory, and market-access barriers remain material.

DOTTI Excipient Strategy, Patent Position, and Commercial Opportunities

DOTTI contains estradiol and is supplied in four delivery rates: 0.025, 0.0375, 0.05, 0.075, and 0.1 mg per day. The system is applied twice weekly for menopausal hormone therapy indications, including treatment of moderate-to-severe vasomotor symptoms and prevention of postmenopausal osteoporosis in appropriate patients [1].

The product uses a transdermal matrix rather than a reservoir design. Estradiol is incorporated into an adhesive layer that controls drug release while maintaining contact with the skin. The FDA-approved labeling identifies acrylic adhesive and silicone adhesive among the inactive components, with polymeric backing and release-liner materials forming the delivery system [1].

What excipients are used in DOTTI patches?

DOTTI’s excipient strategy combines two adhesive chemistries with structural polymer layers.

Component	Functional role	Commercial significance
Acrylic adhesive	Provides adhesion and contributes to estradiol release control	Affects tack, wear time, drug diffusivity, and irritation
Silicone adhesive	Improves skin contact and may support adhesion across variable skin conditions	Can improve tolerability and reduce dependence on aggressive tackifiers
Polymeric backing	Protects the drug-in-adhesive layer and controls handling	Influences moisture transmission, flexibility, and patch integrity
Release liner	Protects the adhesive before application	Affects peel force, dose uniformity, and manufacturing yield
Estradiol	Active pharmaceutical ingredient	Requires uniform distribution and protection from crystallization

The combination of acrylic and silicone adhesives is commercially important because transdermal performance depends on more than estradiol concentration. Adhesive selection affects the partitioning of estradiol into skin, drug diffusion through the matrix, residual drug after wear, and the probability of edge lifting.

The FDA Inactive Ingredient Database can support excipient precedent analysis, but it does not establish that a proposed formulation will have the same adhesion, pharmacokinetic, or skin-tolerability profile as DOTTI [2].

How does DOTTI’s transdermal formulation work?

DOTTI uses a drug-in-adhesive matrix. Estradiol is dispersed within the adhesive layer, and the patch is applied directly to the skin. Delivery depends on:

1. Estradiol solubility in the adhesive phase.
2. Estradiol diffusion through the matrix.
3. Partitioning from the adhesive into the stratum corneum.
4. Adhesive contact over the full wear period.
5. Absence of crystallization or phase separation.
6. Consistent coating thickness and drug loading.

A formulation can fail commercially even if its nominal estradiol dose is correct. Common failure modes include incomplete adhesion, excessive cold flow, skin irritation, visible crystallization, dose loss during storage, and inconsistent release between patch lots.

The main technical optimization is a balance between drug mobility and adhesive performance. Increasing estradiol solubility can improve physical stability but may reduce flux. Increasing drug mobility can improve delivery but can also increase crystallization risk or produce excessive initial release.

What formulation patents could protect a DOTTI competitor?

The active ingredient, estradiol, is old and generally does not provide meaningful composition-of-matter exclusivity for a new transdermal product. Commercial protection is more likely to arise from formulation, process, device, or use claims.

Potential patentable areas include:

Patent area	Example claim focus	Main vulnerability
Adhesive composition	Defined acrylic-silicone ratio or polymer architecture	Obviousness based on known adhesive combinations
Estradiol solubilization	Solvent system, plasticizer, or crystal-inhibition method	Prior-art overlap and enablement limits
Matrix structure	Drug concentration gradient or multilayer adhesive	Difficulty proving technical effect
Manufacturing process	Coating, drying, curing, or lamination parameters	Design-around risk
Patch geometry	Reduced-area patch with specified flux	Limited protection if size follows dose proportionally
Release liner	Low-transfer liner or controlled peel-force system	Often narrow claim scope
Skin adhesion	Performance-defined adhesion across humidity and motion	Testing and claim-construction disputes
Method of use	Dosing schedule, site rotation, or treatment population	Generic carve-out and written-description risks

A commercially useful patent should link the excipient selection to measurable performance, such as improved adhesion after showering, lower skin-removal residue, reduced crystallization, or more consistent estradiol exposure. A claim directed only to a broad acrylic-silicone mixture is likely to face prior-art and obviousness challenges.

When does DOTTI lose exclusivity?

DOTTI’s commercial exclusivity is not determined by the estradiol molecule. It depends on the application pathway, listed patents, regulatory exclusivities, formulation patents, and any applicable pediatric or statutory extensions.

The FDA approved DOTTI under NDA 209940, according to the product labeling and FDA approval materials [1, 3]. FDA Orange Book records should be used to identify any patents listed for the specific NDA, their expiration dates, and any exclusivity codes [3].

The principal exclusivity categories are:

Exclusivity type	Relevance to DOTTI
New chemical entity exclusivity	Generally not applicable to established estradiol
New clinical investigation exclusivity	Possible only if statutory requirements are met
Pediatric exclusivity	Adds six months if granted
Listed formulation or method patent	May delay approval or require a Paragraph IV challenge
Regulatory exclusivity for a 505(b)(2) product	Depends on the approved application and qualifying clinical investigations

A reliable launch date cannot be inferred from the brand’s initial approval date alone. A competitor must evaluate the current Orange Book listing, patent certifications, litigation, settlements, and any regulatory exclusivity still in force.

What is the Orange Book status of DOTTI?

DOTTI is an FDA-approved prescription estradiol transdermal system associated with NDA 209940 [1, 3]. The Orange Book is the controlling source for current patent listings and exclusivity information.

For commercial diligence, the relevant fields are:

• NDA number and application holder.
• Active ingredient and dosage form.
• Listed patents.
• Patent-use codes.
• Expiration dates.
• Exclusivity expiration dates.
• Whether a patent has been delisted or withdrawn.
• Whether an ANDA applicant has submitted a Paragraph IV certification.

Patent status must be reviewed by strength and dosage form because all DOTTI strengths may not necessarily have identical regulatory or patent records.

Which companies are challenging DOTTI?

Public FDA records, court dockets, and Orange Book certifications are required to identify current challengers. A generic applicant may use one of four ANDA certifications:

Certification	Meaning
Paragraph I	No relevant patent information is listed
Paragraph II	Listed patent has expired
Paragraph III	ANDA applicant will wait until patent expiration
Paragraph IV	Listed patent is invalid, unenforceable, or not infringed

A Paragraph IV certification can trigger patent litigation if the NDA holder files suit within the statutory period. For a transdermal product, litigation may focus on adhesive composition, drug loading, release profile, patch construction, or method-of-use claims rather than the estradiol molecule.

No current challenger, litigation outcome, or settlement term should be treated as established without a contemporaneous review of FDA and federal court records.

What generic entry risks exist for DOTTI?

Generic entry risks are higher for a transdermal system than for a conventional oral tablet because sameness involves the delivery system as well as the active ingredient.

The principal risks are:

Bioequivalence risk

The applicant must demonstrate comparable systemic exposure under the applicable FDA pathway. Transdermal products can show variability caused by skin condition, application site, adhesion, temperature, and wear duration.

Adhesion risk

A patch that produces equivalent average exposure but lifts prematurely may face regulatory or commercial problems. Adhesion assessments can include laboratory and clinical measurements.

Residual-drug risk

A patch may retain a substantial fraction of estradiol after use. Residual drug affects safety, disposal, accidental transfer, and dose-delivery comparisons.

Skin-tolerability risk

Acrylic and silicone adhesives can produce different rates of erythema, pruritus, sensitization, and removal trauma. A technically bioequivalent product may still lose market share if patients report more skin reactions.

Manufacturing risk

Critical variables include coating weight, drying temperature, adhesive cure, lamination pressure, liner release, roll-to-roll registration, and pouch seal integrity. Small process changes can alter dose uniformity or release.

FDA’s guidance framework for transdermal and topical delivery systems emphasizes product quality, adhesion, dose delivery, and performance testing [4].

What formulation opportunities exist around DOTTI?

Hypoallergenic adhesive systems

A lower-irritation adhesive could target patients who discontinue patches because of dermatitis or removal pain. The commercial opportunity is strongest if the formulation maintains DOTTI-like estradiol exposure without corticosteroid treatment or frequent site changes.

Smaller patch formats

A smaller patch with equivalent delivery could improve cosmetic acceptability and reduce edge lifting. The formulation challenge is maintaining sufficient drug loading and flux without increasing crystallization.

Improved shower and exercise adhesion

A patch designed for higher humidity, sweating, and mechanical movement could compete on real-world adherence. Claims may focus on adhesion performance rather than a specific adhesive identity.

Reduced residue

Lower adhesive residue can improve patient acceptance and facilitate twice-weekly replacement. This opportunity may require changes to polymer molecular weight, tackifier content, or silicone-acrylic balance.

Longer-wear systems

A once-weekly estradiol patch would offer a meaningful dosing convenience advantage, but it would require a different release and adhesion profile. It could be regulated as a new transdermal product rather than a straightforward DOTTI substitute.

Combination hormone therapy

A combined estradiol-progestogen patch could reduce the number of products used by patients with an intact uterus. The development burden is higher because the formulation must control two active ingredients with different solubility and permeability characteristics.

How strong is the DOTTI patent estate?

The likely strength of protection is concentrated in formulation and manufacturing rather than the estradiol molecule.

Estate component	Relative strength
Estradiol composition-of-matter claims	Low for new entrants because of molecule age
Basic transdermal patch claims	Low to moderate because of extensive prior art
Specific adhesive combination	Moderate if tied to unexpected performance
Process claims	Moderate, but vulnerable to design-around
Adhesion-performance claims	Moderate if testing is reproducible
Method-of-use claims	Variable and dependent on approved labeling
Device or packaging claims	Usually narrow but commercially useful

Patent strength should be assessed claim by claim. The most valuable claims are those that require a competitor to reproduce a difficult-to-substitute adhesive or process condition. Claims based only on broad functional language may be easier to attack for lack of written description or enablement.

How does DOTTI compare with other estradiol delivery systems?

Product type	Main excipient strategy	Commercial advantage	Main weakness
DOTTI patch	Acrylic-silicone drug-in-adhesive matrix	Twice-weekly delivery and established patch format	Skin adhesion and irritation
Oral estradiol	Tablet excipients and immediate or modified release	Low manufacturing complexity	First-pass metabolism and daily dosing
Estradiol gel	Alcoholic or aqueous vehicle with penetration enhancers	No patch adhesive	Transfer risk and daily application
Estradiol spray	Volatile vehicle with metered delivery	Small application area	Dose technique and skin transfer
Vaginal estradiol	Cream, tablet, insert, or ring excipients	Local therapy	Different clinical positioning
Estradiol implant	Polymer or device-based depot	Long dosing interval	Procedure and removal requirements

DOTTI’s competitive position is strongest where patients value a twice-weekly schedule and systemic delivery without oral administration. It is weaker for patients who dislike adhesives, have sensitive skin, or prefer a topical gel.

What FDA regulatory pathway applies to a DOTTI competitor?

A competitor may pursue an ANDA if it can satisfy the applicable requirements for pharmaceutical equivalence and bioequivalence. A product with meaningful formulation, delivery, or clinical differences may require a 505(b)(2) NDA.

A 505(b)(2) strategy may be appropriate for:

• A new adhesive system.
• A different delivery interval.
• A new dose strength or patch size.
• A combination product.
• A modified indication.
• A clinically differentiated skin-tolerability profile.

The regulatory pathway affects development cost, timing, patent certifications, clinical requirements, and the scope of permitted labeling. FDA inactive-ingredient precedent can reduce formulation risk but does not eliminate the need to establish product performance [2, 4].

What licensing and commercial opportunities exist?

No major licensing transaction should be attributed to DOTTI without a documented agreement involving the product, NDA holder, or relevant technology owner. The most plausible licensing targets are:

1. Low-irritation acrylic or silicone adhesive technology.
2. Solvent-free coating and drying processes.
3. Patch-construction technology that improves adhesion.
4. Estradiol crystallization-control systems.
5. Combination-patch platforms.
6. Contract manufacturing capacity for transdermal systems.

Manufacturing access is a strategic barrier. Transdermal production requires validated coating, drying, lamination, pouching, and quality-control infrastructure. A company with a strong adhesive patent but no commercial-scale coating capacity may still face a long path to launch.

What revenue exposure does DOTTI create?

DOTTI-specific revenue is not generally disclosed as a separate public line item by the product owner. Exposure should therefore be modeled through:

• Estradiol transdermal market size.
• DOTTI prescription volume.
• Net price after rebates and discounts.
• Generic or branded-generic competition.
• Share of patients using patches rather than oral or gel products.
• Price erosion after additional transdermal entrants.
• Manufacturing cost per patch.
• Discontinuation rates caused by adhesion or skin reactions.

A differentiated excipient system can protect price only if patients, prescribers, or payers recognize a measurable benefit. Adhesion and tolerability improvements are more defensible commercially when supported by comparative clinical data.

Key Takeaways

• DOTTI is a twice-weekly estradiol drug-in-adhesive transdermal system.
• Its key excipient platform includes acrylic and silicone adhesive components plus polymeric backing and release layers.
• The molecule offers limited new patent value; commercial protection is more likely in adhesive composition, process, patch construction, and performance claims.
• The most attractive formulation opportunities are lower-irritation adhesives, improved wear during exercise or bathing, reduced residue, smaller patches, and longer-wear systems.
• Generic entry requires attention to transdermal bioequivalence, adhesion, skin tolerability, residual drug, and manufacturing consistency.
• The FDA Orange Book and current federal court records are the controlling sources for active patents, Paragraph IV challenges, litigation, and settlement status.
• DOTTI-specific revenue is not separately disclosed, so commercial exposure must be estimated from the broader estradiol transdermal market.

FAQs

Can DOTTI’s acrylic and silicone adhesives be replaced with a single adhesive?

Yes, but the replacement must preserve estradiol stability, delivery rate, adhesion over the labeled wear period, and skin tolerability. A single-adhesive system may require a different drug-loading level or process window.

Is a DOTTI generic required to use the same inactive ingredients?

Not necessarily. An ANDA applicant may use different inactive ingredients if the product meets applicable pharmaceutical equivalence, bioequivalence, quality, and performance requirements. A materially different delivery system may require a 505(b)(2) NDA.

Can a new estradiol patch obtain patent protection without a new active ingredient?

Yes. Protection may be available for a specific adhesive matrix, manufacturing method, patch construction, release profile, or clinically supported use. Broad claims face substantial prior-art risk.

Why do estradiol patches retain drug after removal?

Drug-in-adhesive matrices are designed to deliver estradiol gradually, so residual drug may remain in the matrix after the wear period. Residual content must be assessed for safety, disposal, and comparative product performance.

Is a once-weekly estradiol patch a direct substitute for DOTTI?

No. A once-weekly system would require its own formulation, adhesion, dose-delivery, stability, and regulatory evidence. Its commercial value would come primarily from reduced dosing frequency, not simple substitution of patch size.

References

1. Noven Pharmaceuticals, Inc. (n.d.). DOTTI (estradiol transdermal system) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2019). Transdermal and topical delivery systems: Product development and quality considerations: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/transdermal-and-topical-delivery-systems-product-development-and-quality-considerations-guidance-industry